SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong Sells 8,500 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the company’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $7.26, for a total transaction of $61,710.00. Following the transaction, the chairman owned 3,387,150 shares in the company, valued at approximately $24,590,709. The trade was a 0.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, October 5th, Jurgi Camblong sold 40,172 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.13, for a total transaction of $326,598.36.
• On Thursday, September 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.66, for a total transaction of $65,110.00.
• On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.61, for a total transaction of $64,685.00.
• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.23, for a total transaction of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total transaction of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.29, for a total transaction of $153,356.49.

SOPHiA GENETICS Price Performance

SOPH opened at $7.06 on Thursday. The company has a fifty day moving average price of $7.97 and a two-hundred day moving average price of $6.22. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a 52 week low of $3.75 and a 52 week high of $8.98. The firm has a market capitalization of $592.26 million, a PE ratio of -6.14 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Analyst Ratings Changes

SOPH has been the topic of a number of recent analyst reports. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research boosted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of SOPHiA GENETICS in a research note on Monday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Trading of SOPHiA GENETICS

Several hedge funds have recently bought and sold shares of SOPH. AWM Investment Company Inc. bought a new stake in shares of SOPHiA GENETICS during the second quarter worth $9,809,000. Principal Financial Group Inc. raised its holdings in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after acquiring an additional 9,800 shares during the period. Hodges Capital Management Inc. bought a new stake in SOPHiA GENETICS in the 1st quarter valued at $2,157,000. Sei Investments Co. bought a new stake in SOPHiA GENETICS in the 1st quarter valued at $1,772,000. Finally, 1492 Capital Management LLC lifted its position in SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after acquiring an additional 17,406 shares in the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.